Document is current
Any future updates will be listed below
-
Authors
Nakamura, Akinobu
Miyoshi, Hideaki
Kameda, Hiraku https://orcid.org/0000-0003-1870-6688
Yamashita, Kumiko
Kurihara, Yoshio
-
Clinical Trials BETA
Clinical trials referenced in this document:
umin000035263 at UMIN JapanDocuments that mention this clinical trial
Impact of sodium–glucose cotransporter 2 inhibitors on renal function in participants with type 2 diabetes and chronic kidney disease with normoalbuminuria
https://doi.org/10.1186/s13098-020-0516-9
- License Information
-
More Information
Article History
Received: 28 September 2019
Accepted: 5 January 2020
First Online: 10 January 2020
Ethics approval and consent to participate
: The study was conducted with approval from the Institutional Review Board of the Japan Clinicians Diabetes Association, and registered with the University Hospital Medical Information Network (UMIN; number UMIN000035263).
: Not applicable.
: AN. has obtained research support from Mitsubishi Tanabe Pharma Co. and Ono Pharmaceutical Co. Ltd. H.M. has received honoraria for lectures from Astellas Pharma Inc., Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., MSD, Novartis Pharma, Novo Nordisk Pharma, Kowa Pharmaceutical Co. Ltd., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Sanofi, and has received research funding from Astellas Pharma Inc., Daiichi Sankyo, Dainippon Pharma Co., Eli Lilly, Mitsubishi Tanabe Pharma Co., Novo Nordisk Pharma, Kowa Pharmaceutical Co., Abbott Japan Co., Nippon Boehringer Ingelheim Co., Ono Pharmaceutical Co. Ltd., and Taisho Pharmaceutical Co. Ltd. Y.K. has received honoraria for lectures from Astellas Pharma Inc., AstraZeneca, Mitsubishi Tanabe Pharma Co. Ltd., MSD, Ono Pharmaceutical Co. Ltd., Sanofi, Shionogi & Co. Ltd., Taisho Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Co. Ltd. H.K. and K.Y.
